Who this is for
Market access and payer strategy
See formulary position and coverage criteria for your brand and its competitors in one place, and hear about changes when they happen rather than at the next quarterly review.
Pricing and contracting
Follow list price movements and the pricing context across the market basket, so contracting decisions are made with the whole picture in view.
HEOR and value teams
Follow health technology assessment decisions and the evidence they asked for, so value dossiers and submissions answer the questions assessors actually raise.
Brand teams and field reimbursement
Understand where access is limiting growth, and give field teams accurate information about what each payer requires.
What changes for the team
How the work tends to look today, and how it looks once Pharma Landscape 360 is in place.
How Pharma Landscape 360 helps
Coverage and formulary position by payer
See where your brand and its competitors sit on each formulary that matters to you: tier, restrictions, and the utilization management attached. Medicaid coverage is included, so the team can see at a glance where access is strong and where it is limiting growth.
Criteria changes, caught early
Prior authorization requirements, step therapy, quantity limits and other restrictions change without much notice. When they do, for your brand or a competitor, the change is flagged with what it was before and what it is now. A tighter criterion found the week it is published can be answered. One found three months later has already cost patients.
Pricing in context
Follow list price movements across your market basket over time, alongside the access position of each product. Pricing and contracting discussions start from a shared view of the market rather than from separate spreadsheets.
HTA decisions outside the United States
Health technology assessment decisions and recommendations in the markets you follow are tracked in the same place as US coverage, including what the assessors asked for and how competitors fared. Global value teams see how the evidence is being judged in each market.
Connecting access to the forecast
Access changes matter because of what they do to patients and revenue. The coverage picture sits next to the patient funnel and the forecast drivers, so the commercial team can see which change affects which assumption, and the forecast reflects the access situation as it is.
An example
A national PBM adds a step edit
On a Tuesday a large pharmacy benefit manager updates its criteria for your therapeutic class. From the start of next quarter, patients will need to try a competitor's product before your brand is covered.
The change is flagged the same day for the access lead and the brand lead, with the old and new criteria side by side and the competitor that benefits. The access team can start sizing the exposure straight away. Field reimbursement has an accurate summary to share with offices before the first rejections arrive.
The forecasting team updates the assumption that the change affects, and by the end of the week leadership has a clear view of the exposure and the response, while there is still a quarter to act.
Common questions
If yours isn't here, ask us directly.
What is market access intelligence?
It is the ongoing work of tracking how payers and health systems cover and pay for a medicine: formulary position, coverage criteria, pricing and, outside the US, health technology assessment decisions. Access teams use it to spot risks early and to plan their response.
Which changes does it flag?
Changes to formulary status, prior authorization requirements, step therapy, quantity limits and other restrictions for your brand and its competitors, along with pricing movements and new HTA decisions in the markets you follow.
Does it cover markets outside the United States?
Yes. International HTA decisions and access developments are followed alongside US coverage, for the countries you choose.
Can field reimbursement and sales teams use it?
Yes. They get a clear, current view of what each payer requires, which keeps the information they give to offices accurate and consistent.
Does it help with payer conversations?
It gives the access team a current picture of each payer's position and how competitors are covered, which is the starting point for any negotiation or value discussion.
How quickly can we get started?
A few weeks. The main step is agreeing the brands, competitors, payers and markets to follow, and who should be told about which changes.
Further reading
Glossary: Formulary, Gross-to-net, Health technology assessment, Health economics and outcomes research, Pharmacy benefit manager, Prior authorization, Step therapy